Table 1.

Baseline characteristics in the training and validation cohorts.

Variables	Training cohort (n = 222)	Validation cohorts (n = 163)
		Cohort 1 (n = 105)	Cohort 2 (n = 26)	Cohort 3 (n = 16)	Cohort 4 (n = 16)
Age, mean (SD), year	48 (11)	54 (12)	48 (12)	47 (11)	48 (11)
Male, n (%)	151 (68·0%)	76 (72·4%)	19 (73.1%)	8 (50·0%)	10 (62·5%)
BMI, mean (SD), kg/m2	23·0 (3·1)	23.0 (3·3)	22·9 (3·0)	22 (3·9)	24·8 (4·3)
HVPG, mean (SD), mmHg	16·1 (6·1)	24.7 (10·9)	15·1 (5·1)	11·4 (5.8)	13·0 (4·1)
HVPG ≥10 mmHg, n (%)	182 (82.0%)	101 (96·2%)	21 (80·8%)	11 (68·8%)	12 (75·0%)
Etiology, n (%)
Hepatitis B virus	169 (76·1%)	71 (67·6%)	21 (80·8%)	9 (56·3%)	8 (50·0%)
Alcohol	17 (7·7%)	11 (10·5%)	1 (3·8%)	2 (12·5%)	2 (12·5%)
Hepatitis C virus	9 (4·1%)	5 (4·8%)	0	0	3 (18·8%)
Other	27 (12·2%)	18 (17·1%)	4 (15·3%)	5 (31·3%)	3 (18·8%)
Child-Pugh score, n (%)
Class A	181 (81·5%)	4 (3·8%)	18 (69·2%)	10 (62·5%)	9 (56·3%)
Class B	34 (15·3%)	75 (71·4%)	7 (26·9%)	4 (25·0%)	3 (18·8%)
Class C	7 (3·2%)	26 (24·8%)	1 (3·8%)	2 (12·5%)	4 (25·0%)
AST (μkat/L), mean (SD)	0·64 (0·39)	0.58 (0.37)	0·91 (1·13)	0·58 (0·31)	0·49 (0·18)
ALT (μkat/L), mean (SD)	0·48 (0·35)	0·42 (0·31)	0·98 (1·71)	0·61 (0·27)	0·45 (0·37)
Albumin (g/L), mean (SD)	35·5 (4·3)	35·4 (5·7)	35·4 (4·9)	39·4 (6·3)	37·3 (5·5)
TBIL (μmol/L), mean (SD)	19·2 (11·9)	27·6 (18·5)	24·7 (27·0)	23·6 (10·5)	28·2 (12·4)
INR, mean (SD)	1·15 (0·14)	1·3 (0·2)	1·4 (0·39)	1·37 (0·22)	1·21 (0·16)
PLT (109/L), mean (SD)	93·4 (104·7)	83·3 (53·0)	182·2 (215·7)	54·0 (34·1)	83·5 (54·5)

SD, standard deviation; y, year; BMI, body mass index; HVPG, hepatic venous pressure gradient; AST, aspartate aminotransferase.

ALT, alanine aminotransferase; TBIL, total bilirubin; INR, international normalized ratio; PLT, platelet count.